CLOS
PACB icon

Compagnie Lombard Odier SCmA’s Pacific Biosciences PACB Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,500
Closed -$370K – 663
2021
Q2 		$437K Buy
12,500
+10,500
+525% +$305K 0.01% 246
2021
Q1 		$67K Buy
+2,000
New +$70K ﹤0.01% 481
2019
Q3 		– Sell
-10,000
Closed -$61K – 541
2019
Q2 		$61K Hold
10,000
– – ﹤0.01% 350
2019
Q1 		$72K Hold
10,000
– – ﹤0.01% 378
2018
Q4 		$74K Sell
10,000
-115,000
-92% -$729K ﹤0.01% 354
2018
Q3 		$676K Sell
125,000
-30,000
-19% -$129K 0.02% 176
2018
Q2 		$552K Sell
155,000
-25,000
-14% -$69.4K 0.02% 200
2018
Q1 		$366K Buy
180,000
+30,000
+20% +$77.9K 0.01% 243
2017
Q4 		$395K Hold
150,000
– – 0.01% 252
2017
Q3 		$786K Buy
150,000
+3,000
+2% +$12.9K 0.03% 224
2017
Q2 		$524K Sell
147,000
-22,200
-13% -$89.5K 0.02% 264
2017
Q1 		$875K Sell
169,200
-3,000
-2% -$14.7K 0.03% 230
2016
Q4 		$654K Buy
172,200
+37,200
+28% +$270K 0.02% 293
2016
Q3 		$1.21M Buy
135,000
+3,000
+2% +$25.1K 0.04% 243
2016
Q2 		$927K Buy
132,000
+48,400
+58% +$442K 0.03% 274
2016
Q1 		$713K Buy
83,600
+35,600
+74% +$350K 0.02% 300
2015
Q4 		$630K Sell
48,000
-76,500
-61% -$686K 0.02% 290
2015
Q3 		$456K Buy
124,500
+33,000
+36% +$161K 0.02% 287
2015
Q2 		$528K Buy
91,500
+3,500
+4% +$20.3K 0.02% 300
2015
Q1 		$514K Sell
88,000
-4,000
-4% -$27.6K 0.02% 306
2014
Q4 		$721K Sell
92,000
-52,341
-36% -$335K 0.03% 227
2014
Q3 		$709K Buy
144,341
+42,841
+42% +$224K 0.03% 245
2014
Q2 		$627K Buy
101,500
+9,000
+10% +$45K 0.02% 278
2014
Q1 		$495K Buy
+92,500
New +$585K 0.02% 325

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Compagnie Lombard Odier SCmA's PACB Position: Q3 2021 in Review

Compagnie Lombard Odier SCmA sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 12,500 shares — an estimated $370K sold.

Compagnie Lombard Odier SCmA first reported a position in PACB in Q1 2014 and held it in 24 quarters. The position peaked at $1.21M in Q3 2016. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 12,500 Pacific Biosciences shares in Q3 2021, an estimated $370K.
  • Compagnie Lombard Odier SCmA first reported a position in Pacific Biosciences in Q1 2014 and held it in 24 quarters.
  • Compagnie Lombard Odier SCmA's Pacific Biosciences position peaked at $1.21M in Q3 2016.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2021, filed 28 Oct 2021.